View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 2, 2022

NorthSea begins Phase I trial of liver disease asset in healthy volunteers

The final data from the Phase I trial recruiting 90 healthy participants is expected in the third quarter of 2022.

NorthSea Therapeutics has commenced a Phase I clinical trial of SEFA-6179 in adult subjects, intending to obtain a preliminary orphan indication to treat intestinal failure-associated liver disease (IFALD).

The final data from the Phase I trial recruiting healthy volunteers is expected in the third quarter of 2022. It will facilitate the start of an international Phase II trial in individuals with IFALD. The Phase II trial is planned to begin in the first quarter of 2023.

The placebo-controlled, randomised, single and multiple ascending dose Phase I trial will assess the safety, tolerability and pharmacokinetics of SEFA-6179. It plans to enrol nearly 90 healthy subjects in the UK.

An oral, synthetic, medium-chain fatty acid analog (MCFA), SEFA-6179 is intended to preserve the ease of transport to the liver as well as into cells that is characteristic of MCFAs. 

This is also designed to provide improved pharmacological impact by averting quick metabolism.

In various preclinical models, the molecule directly acts on the liver and was found to impact cholestasis, steatosis, and fibrosis. 

NorthSea Therapeutics CEO Rob de Ree said: “The commencement of this trial is a key milestone in NST’s journey to become a multi-asset company with a robust clinical pipeline of SEFAs. 

“We are excited to develop our first candidate for an orphan indication, especially for one where patients currently have no therapeutic options available.”

In pre-clinical studies, SEFA-6179 was found to have favourable effects in averting parenteral nutrition-induced cholestasis development and liver injury linked to IFALD.

Characterised by hepatic inflammation, cholestasis and steatosis development, IFALD is a multifactorial condition in individuals with intestinal failure and/or substantial resection. 

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU